SSY Group Reports Decline in Q1 2025 Financial Performance

SSY Group ( (HK:2005) ) just unveiled an update.

SSY Group Limited announced a significant decline in its unaudited operating results for the first quarter of 2025, with a 36.9% decrease in turnover compared to the same period in 2024. The drop in sales volume of intravenous infusion solutions and ampoule injections contributed to a 50.6% decrease in gross profit and a 59.5% decrease in profit attributable to shareholders. This downturn in financial performance could impact the company’s market positioning and stakeholder confidence.

The most recent analyst rating on (HK:2005) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on SSY Group stock, see the HK:2005 Stock Forecast page.

More about SSY Group

SSY Group Limited is a company incorporated in the Cayman Islands with limited liability, primarily operating in the pharmaceutical industry. The company focuses on the production and sale of intravenous infusion solutions, ampoule injections, bulk pharmaceuticals, oral preparations, and medical materials, with a significant market presence in the People’s Republic of China.

Average Trading Volume: 8,269,100

Technical Sentiment Signal: Sell

Current Market Cap: HK$8.74B

Learn more about 2005 stock on TipRanks’ Stock Analysis page.